Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology · 10.03.2023 · 41 (8) · 1600-1609
DOI: 10.1200/jco.21.02734 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.03.2023. Verfasst von Pieter Sonneveld und 18 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Multiple Myeloma, Neutropenia. Die Arbeit wurde bisher 131-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the final analysis for overall survival (OS). METHODS CASTOR was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line of prior therapy were randomly assigned to Vd (up to eight cycles) with or without daratumumab (until disease progression). After positive primary analysis and protocol amendment, patients receiving Vd were offered daratumumab monotherapy after disease progression. RESULTS At a median (range) follow-up of 72.6 months (0.0-79.8), significant OS benefit was observed with D-Vd (hazard ratio, 0.74; 95% CI, 0.59 to 0.92; P = .0075). Median OS was 49.6 months with D-Vd versus 38.5 months with Vd. Prespecified subgroup analyses demonstrated an OS advantage with D-Vd versus Vd for most subgroups, including patients age ≥ 65 years and patients with one or two prior lines of therapy, International Staging System stage III disease, high-risk cytogenetic abnormalities, and prior bortezomib treatment. The most common (≥ 10%) grade 3/4 treatment-emergent adverse events with D-Vd versus Vd were thrombocytopenia (46.1% v 32.9%), anemia (16.0% v 16.0%), neutropenia (13.6% v 4.6%), lymphopenia (10.3% v 2.5%), and pneumonia (10.7% v 10.1%). CONCLUSION D-Vd significantly prolonged OS in patients with RRMM, with the greatest OS benefit observed in patients with one prior line of therapy. To our knowledge, our results, together with the OS benefit observed with daratumumab plus lenalidomide and dexamethasone in the phase III POLLUX study, demonstrate for the first time an OS benefit with daratumumab-containing regimens in RRMM (ClinicalTrials.gov identifier: NCT02136134 [CASTOR]).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
- Mayo Clinic Florida, Jacksonville, FL.
- Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany.
- Winship Cancer Institute, Emory University, Atlanta, GA.
- Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
- Ankara University, Ankara, Turkey.
ORCID-Profile: Pieter Sonneveld, Ajay K Nooka, Tamas Masszi, Meral Beksac, Vania Hungria, Markus Munder, Maria-Victoria Mateos, Tomer M Mark, Mark-David Levin, Xue Gai, Andrew Spencer
Zitieren
APA
Sonneveld, P., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., Mark, T. M., Levin, M. D., Ahmadi, T., Qin, X., Garvin Mayo, W., Gai, X., Carey, J., Carson, R., & Spencer, A. (2023). Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology, 41(8), 1600-1609. https://doi.org/10.1200/jco.21.02734
Vancouver
Sonneveld P, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology. 2023;41(8):1600-1609. doi:10.1200/jco.21.02734
BibTeX
@article{Sonneveld2023,
author = {Sonneveld, Pieter and Chanan-Khan, Asher and Weisel, Katja and Nooka, Ajay K and Masszi, Tamas and Beksac, Meral and Spicka, Ivan and Hungria, Vania and Munder, Markus and Mateos, Maria-Victoria and Mark, Tomer M and Levin, Mark-David and Ahmadi, Tahamtan and Qin, Xiang and Garvin Mayo, Wendy and Gai, Xue and Carey, Jodi and Carson, Robin and Spencer, Andrew},
title = {Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {8},
pages = {1600--1609},
doi = {10.1200/jco.21.02734}
}
EUVIMED